Unlock instant, AI-driven research and patent intelligence for your innovation.

Treatment with gemcitabine and EGFR-inhibitor

A technology of gemcitabine and kinase inhibitors, applied in medical preparations containing active ingredients, organic active ingredients, pharmaceutical formulations, etc., can solve problems such as narrow therapeutic index

Inactive Publication Date: 2007-05-09
F HOFFMANN LA ROCHE & CO AG
View PDF50 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Instead, most have very narrow therapeutic indices

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment with gemcitabine and EGFR-inhibitor
  • Treatment with gemcitabine and EGFR-inhibitor
  • Treatment with gemcitabine and EGFR-inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0021] The term "carcinoma" in an animal refers to the presence of cells with typical properties of carcinogenic cells, such as uncontrolled proliferation, immortalization, metastatic potential, rapid growth and proliferation rates, and certain morphological properties. Typically, cancer cells take the form of tumors, but such cells can exist alone in animals, or circulate in the blood as separate cells, such as leukemia cells.

[0022] As used herein, unless otherwise indicated, "abnormal cell growth" refers to cell growth independent of normal regulatory mechanisms (eg, loss of contact inhibition). It includes the abnormal growth of 1. neoplastic cells (tumors) that proliferate by expressing mutated tyrosine kinases or overexpressing tyrosine kinase receptors; 2. benign and malignant cells of other proliferative diseases in which Aberrant tyrosine kinase activation; 4. Any tumor that proliferates through receptor tyrosine kinases; 5. Any tumor that proliferates through aberr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a method for the preparation of a medicament for the treatment of tumors or tumor metastases, characterized in that a therapeutically effective amount of an EGFR kinase inhibitor and gemcitabine is used, with or without additional agents or treatments, such as other anticancer drugs or radiation therapy. The present invention also encompasses pharmaceutical compositions comprising the combination of an EGFR kinase inhibitor and gemcitabine, in combination with a pharmaceutically acceptable carrier. An example of a preferred EGFR kinase inhibitor that can be used in the practice of the present invention is the compound erlotinib hydrochloride (also known as Tarceva TM ).

Description

Background of the invention [0001] The present invention relates to compositions intended for the treatment of cancer and methods of preparing the medicament. In particular, the present invention relates to a process for the preparation of a medicament comprising gemcitabine and an epidermal growth factor receptor (EGFR) kinase inhibitor. [0002] Cancer is the general name for a wide variety of cellular malignancies characterized by uncontrolled growth, lack of differentiation, and the ability to invade local tissues and metastasize. These malignancies affect every tissue and organ in the body at varying rates. [0003] A variety of therapeutic agents have been developed over the past few decades for the treatment of various types of cancer. The most commonly used classes of anticancer agents include: DNA alkylating agents (eg, cyclophosphamide, ifosfamide), antimetabolites (eg, methotrexate, folate antagonists, and 5-fluorouracil, pyrimidine antagonists), microbes Tube di...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/513A61K31/517A61K31/5377A61K31/519A61K31/4706A61P35/00A61K31/498A61K31/7072
CPCA61K31/513A61K31/7072A61K31/498A61K31/519A61K31/5377A61K31/517A61K31/4706A61P35/00A61P35/04A61P43/00A61K2300/00
Inventor B·希金斯K·科林斯基
Owner F HOFFMANN LA ROCHE & CO AG